Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).

It is a hot clinical issue whether newly approved antimicrobial agents such as daptomycin, linezolid, quinupristin/dalfopristin (synercid) and tigecycline are active enough to be used for infections caused by vancomycin resistant bacteria. We performed susceptibility tests for mupirocin, which is in widespread clinical use in Korea, and four new antimicrobials, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline, against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium isolated from Korean patients in 1998 and 2005 to evaluate and compare the in vitro activity of these antimicrobials. Among these agents, quinupristin/dalfopristin, which is rarely used in hospitals in Korea, showed relatively high resistance to several vancomycin-resistant enterococci (VRE) isolated in 2005. Likewise, daptomycin, linezolid and tigecycline have not yet been in clinical use in Korea. However, our results showed that most of the 2005 VRE isolates were already resistant to linezolid and daptomycin (highest minimum inhibitory concentration (MIC) value >100 microg/ml). Compared with the other four antimicrobial agents tested in this study, tigecycline generally showed the greatest activity against VRE. However, four strains of 2005 isolates exhibited resistance against tigecycline (MIC >12.5 microg/ml). Almost all VRE were resistant to mupirocin, whereas all E. faecium isolated in 1998 were inhibited at concentrations between 0.8 to approximately 1.6 microg/ml. In conclusion, resistances to these new antimicrobial agents were exhibited in most of VRE strains even though these new antibiotics have been rarely used in Korean hospitals.

[1]  B. Kang,et al.  Occurrence of the Van Genes inEnterococcus faecalis andEnterococcus faecium from clinical isolates in Korea , 2007, Archives of pharmacal research.

[2]  Y. Nakajima,et al.  A Prospective, Randomized Study , 2006 .

[3]  G. Attila,et al.  Insertion/deletion polymorphism of the angiotensin converting enzyme gene in coronary artery disease in southern Turkey. , 2005, Journal of biochemistry and molecular biology.

[4]  Ronald N. Jones,et al.  Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. , 2005, Diagnostic microbiology and infectious disease.

[5]  Ronald N. Jones,et al.  Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). , 2005, Diagnostic microbiology and infectious disease.

[6]  Patrick F. Smith,et al.  Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. , 2005, Diagnostic microbiology and infectious disease.

[7]  Ronald N. Jones,et al.  Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. , 2005, Diagnostic microbiology and infectious disease.

[8]  P. Hsueh,et al.  Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents , 2005, International Journal of Antimicrobial Agents.

[9]  Ronald N. Jones,et al.  Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. , 2005, Diagnostic microbiology and infectious disease.

[10]  E. Culebras,et al.  In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates. , 2005, Journal of Antimicrobial Chemotherapy.

[11]  P. Bradford,et al.  In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. , 2005, Diagnostic microbiology and infectious disease.

[12]  K. Park,et al.  The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. , 2005, Journal of biochemistry and molecular biology.

[13]  D. Nathwani.  Tigecycline: clinical evidence and formulary positioning. , 2005, International journal of antimicrobial agents.

[14]  F. Tally,et al.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. , 2005, The Journal of antimicrobial chemotherapy.

[15]  Ronald N. Jones,et al.  Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). , 2004, Diagnostic microbiology and infectious disease.

[16]  Ronald N. Jones,et al.  Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. , 2004, Diagnostic microbiology and infectious disease.

[17]  H. Gold,et al.  Antimicrobial resistance to linezolid. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Rybak,et al.  Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. , 2004, Diagnostic microbiology and infectious disease.

[19]  R. Wenzel,et al.  The antibiotic pipeline--challenges, costs, and values. , 2004, The New England journal of medicine.

[20]  H. Kantarjian,et al.  Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. , 2004, The Journal of antimicrobial chemotherapy.

[21]  Ronald N. Jones,et al.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. , 2004, The Journal of antimicrobial chemotherapy.

[22]  N. Silverberg,et al.  Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. , 2004, Clinics in dermatology.

[23]  Robin Patel.  Clinical impact of vancomycin-resistant enterococci. , 2003, The Journal of antimicrobial chemotherapy.

[24]  G. Eliopoulos,et al.  Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus , 2003, Antimicrobial Agents and Chemotherapy.

[25]  Ronald N. Jones.  Global Epidemiology of Antimicrobial Resistance among Community-Acquired and Nosocomial Pathogens: A Five-Year Summary from the SENTRY Antimicrobial Surveillance Program (1997-2001) , 2003, Seminars in respiratory and critical care medicine.

[26]  S. Choi,et al.  Isolation, Identification and Characterization of Vancomycin-Resistant Enterococci from Raw Milk , 2002 .

[27]  C. Chen,et al.  INSERTION/DELETION POLYMORPHISM OF THE ACE GENE IS ASSOCIATED WITH T2D , 2002 .

[28]  K. Rolston,et al.  Treatment of Vancomycin-Resistant Enterococcal Infections in the Immunocompromised Host: Quinupristin-Dalfopristin in Combination with Minocycline , 2001, Antimicrobial Agents and Chemotherapy.

[29]  C. Seong,et al.  Prevalence and Antibiotic Susceptibility of Vancomycin-Resistant Enterococci in Chicken Intestines and Fecal Samples from Healthy Young Children and Intensive Care Unit Patients , 2001 .

[30]  R. Akins,et al.  Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V , 2001, Antimicrobial Agents and Chemotherapy.

[31]  Steven D. Brown,et al.  Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. , 2000, Diagnostic microbiology and infectious disease.

[32]  J. M. Kim,et al.  Vancomycin-resistant enterococcal infections in Korea. , 1998, Yonsei medical journal.

[33]  W. Witte.  Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. , 1997, Ciba Foundation symposium.

[34]  H. Claus,et al.  vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. , 1995, FEMS microbiology letters.

[35]  R. Gaynes,et al.  An overview of nosocomial infections, including the role of the microbiology laboratory , 1993, Clinical Microbiology Reviews.

[36]  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. , 1993, MMWR. Morbidity and mortality weekly report.

[37]  R. Moellering.  Emergence of Enterococcus as a significant pathogen. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.